Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity by Akinwande, Olaguoke et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
7-1-2017 
Chemoembolization versus radioembolization for the treatment 
of unresectable intrahepatic cholangiocarcinoma in a single 






See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Olaguoke Akinwande, Veer Shah, Abigail Mills, Christopher Noda, Eric Weiner, Gretchen Foltz, and Nael 
Saad 
75ISSN 2045-0923Hepat. Oncol. (2017) 4(3), 75–81
part of
10.2217/hep-2017-0005 © 2017 Future Medicine Ltd
ReseaRch aRticle
Chemoembolization versus 
radioembolization for the treatment 
of unresectable intrahepatic 
cholangiocarcinoma in a single institution 
image-based efficacy and comparative 
toxicity
Olaguoke Akinwande*,‡,1, Veer Shah‡,1, Abigail Mills1, Christopher Noda1, 
Eric Weiner2, Gretchen Foltz1 & Nael Saad1
1Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. 
Louis, MO, USA 
2Washington University School of Medicine in St. Louis, St. Louis, MO, USA 
*Author for correspondence: Tel.: +1 314 362 2978; oakinwa@wustl.edu 
‡Authors contributed equally
aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of 
unresectable intrahepatic cholangiocarcinoma (UICC). Materials & methods: Institutional 
Review Board-approved, retrospective search was performed. Forty patients with UICC 
were treated with either Y90 (n = 25, 39 treatments) or CE (n = 15, 35 treatments). Comparative 
analysis was performed using Student’s t and fisher-exact tests. Multivariable-logistic 
regression was also performed. Results: Median ages were 60 and 64  years for CE and 
Y90 groups, respectively (p = 0.798). Patient variables including age, Eastern Cooperative 
Oncology Group score, tumor burden, extra-hepatic disease, prior chemotherapy and 
prior surgery were similar between groups. Adverse events were similar in both groups 
(CE 20%, Y90 26%; p  >  0.9). Overall response rate (CE 6%, Y90 4%; p  >  0.9) and disease 
control rate (CE 46%, Y90 48%; p > 0.9) were statistically similar. Multilogistic regression 
did not identify any variables that correlated with disease control rate, including Eastern 
Cooperative Oncology Group score and tumor burden. conclusion: Our observation 
shows that CE and Y90 display similar toxicity and disease control in the treatment of UICC.
First draft submitted: 15 March 2017; Accepted for publication: 22 August 2017; Published 
online: 30 October 2017
summary points
 ●  Comparative treatment-related adverse events from radioembolization or chemoembolization were statistically insignificant, and should 
therefore not be used to dictate the treatment modality.
 ●  The tumor response rate and disease control rate from both radioemboization and chemoembolization were similar.
 ●  Logistic regression did not reveal any background factor to independently associate with disease control after transarterial therapy.
 ●  Both current and prior chemotherapy regimens did not have a significant effect on outcomes from the procedure.
 ●  Eastern Cooperative Oncology Group score did not correlate with treatment response to either modality, although our study is limited by 
its retrospective nature and small patient population.
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Intrahepatic cholangiocarcinoma (ICC) is a 
rare malignancy arising from the epithelial 
cells of intrahepatic bile ducts. It is the second 
most common primary liver malignancy after 
hepatocellular carcinoma (HCC) in the USA, 
with an annual age-adjusted incidence of 1–2 
cases per 100,000 [1,2]. For patients with local-
ized disease, hepatic resection is the standard 
of care [3,4]. The ability to achieve complete 
margin-negative surgical resection (RO resec-
tion margin) for node-negative disease may 
confer a 5-year survival range of 30–63% [5,6]. 
Unfortunately, <50% of patients present with 
early-stage disease that is suitable for surgical 
resection [7]. In addition, despite aggressive 
resection, at least 50% of patients undergoing 
resection experience recurrence of tumor with 
the mean time to recurrence being ranging 
from 10 to 20 months [8]. For these patients the 
prognosis is poor, with median survival ranging 
from 3 to 8 months [9,10].
Systemic therapy, particularly gemcitabine-
based regimens, is frequently used for these 
patients with advanced ICC; however, the role 
of systemic chemotherapy is still evolving with 
the current regimens providing only modest 
survival benefit, with a reported response rate 
of 10–30% [11,12].
Over the years, arterially directed embolic 
therapy has increasingly been utilized for the 
treatment of this patient population. Hepatic 
arterial infusion (HAI), drug-eluting beads 
(DEB), radioembolization (Y90) and chem-
oembolization (CE) utilize differential perfusion 
physiology to treat liver tumors with minimal 
collateral damage [13]. Part of the optimism for 
this strategy is derived from the efficacy of this 
treatment in patients with HCC. Given that 
ICC is also a primary liver malignancy, there is 
reason to expect good response with intra-arte-
rial therapy (IAT). While both Y90 and CE have 
been shown to be efficacious to treat unresect-
able ICC in this patient population, there are 
few studies that have reported on the safety and 
efficacy of these modalities [10,14–16], and there 
is insufficient evidence concerning the superior 
treatment device [8].
Given the challenge of obtaining good treat-
ment response in this population, it is important 
to assess the comparative performance of these 
treatment modalities to optimize management 
and to direct the focus of future research in this 
arena. Herein, we compare the image-based effi-
cacy (i.e, tumor response based on imaging) and 
toxicity of Y90 and CE for unresectable ICC in a 
single center setting. Being that cholangiocarci-
noma is a relatively hypovascular tumor [17], we 
hypothesize that Y90 will perform better given 
that its efficacy is not dependent on emboliza-




This study was Institutional Review Board 
approved. We performed a retrospective search 
for patients with unresectable ICC treated 
with IAT at our institution from August 2001 
to July 2016. Forty consecutive patients were 
treated with either Y90 (n = 25) or CE (n = 15). 
A multidisciplinary team comprised of surgi-
cal oncologists, medical oncologists, radiation 
oncologists and interventional radiologists eval-
uated eligible patients to determine the type of 
therapy. Our pretherapy evaluation comprised 
of computed tomography (Siemens Healthcare) 
using 3–5 mm thick slices or MRI (Siemens 
Healthcare, IL, USA) using 3–10 mm thick 
slices. Tumor burden was assessed by evaluat-
ing target lesion size and number, presence of 
nontarget lesions and presence of lymph nodes 
on imaging. Patients were grouped according 
table 1. Baseline patient characteristics.
Patient characteristics ce Y90 
Number of patients 15 25
Age (years):    
– Median 60 64
– Range 38–89 29–87
Gender (n), %:    
– Male 8 (53%) 8 (32%)
Hepatitis (n) 3 9
ECOG score:    
– 0–2 14 24
– >2 1 1
Tumor extent (n):    
– 1–25% 2 12
– 26–50% 5 9
– 51–75% 2 0
– >75% 0 0
– Unknown 6 4
Extrahepatic disease (n) 4 11
Prior chemotherapy (n) 13 16
Concurrent chemotherapy (n) 5 4
Prior liver surgery/RFA (n) 4 5
Y90: Radioembolization; CE: Chemoembolization; ECOG: Eastern Cooperative Oncology Group; 
RFA: Radiofrequency ablation.
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to their index intra-arterial treatment modality 
regardless of treatment crossover. Forty consecu-
tive patients were included in this study of which 
15 patients were treated with CE and 25 patients 
were treated with Y90 (table 1).
●● hepatic arterial therapy technique
CE technique was performed in a conventional 
fashion or using DEB. The specifics of the 
embolization device, embolic used and chemo-
therapeutic agents are listed in table 2. Patients 
were typically planned for two to three treat-
ment cycles based on the extent of liver tumor 
involvement. Treatments were spaced in 2–3-
week intervals depending on patient toxicity. 
For Y90, visceral angiogram was performed to 
evaluate arterial anatomy and determine optimal 
placement of the microcatheter for embolization. 
99mTC-labeled macroaggregated albumin was 
delivered through the hepatic artery to assess 
hepatopulmonary shunting and to detect haz-
ardous extrahepatic deposition. Shunt fractions 
were calculated using planar scintigraphy. Y90 
therapy was delivered as per manufacturer’s 
recommendation [18]. Placement of the delivery 
microcatheter for both CE and Y90 was based 
on the extent and location of liver disease, 
and included whole liver, lobar or segmental 
 treatment (table 2).
●● study schedule & outcome measures
Toxicity was recorded per standards and ter-
minology set forth by the Cancer Therapy 
Evaluation Program’s Common Terminology 
Criteria for Adverse Events version 3.0. Our fol-
low-up protocol consisted of a CT or MRI scan 
within 1-month post-treatment. Tumor response 
rates were measured according to modified 
Response Evaluation Criteria in Solid Tumors 
(mRECIST) criteria [19]. Modified RECIST 
was specifically chosen because it had been 
shown to correlate with survival and it outper-
forms RECIST in this patient population [20]. 
Overall response rate refers to the combination 
of complete and partial responders per mRE-
CIST. Disease control rate (DCR) refers to the 
combination of all responders and those with 
stable disease.
●● statistical analysis
An as-treated analysis was performed. The 
Student’s t test was used for continuous data. The 
Fisher’s exact test was used for categorical data 
comparisons (two-tailed). Multivariable logistic 
regression was used to evaluate the association 
between independent variables and DCR. DCR 
was chosen instead of overall response given the 
low response rate and the relatively small size of 
the study sample (a regression model based on 
overall response would be unacceptably biased). 
p-values <0.05 were considered statistically sig-
nificant. All statistics were calculated using JMP 
software (JMP, SAS Institute, Inc, NC USA).
Results
●● Patient characteristics
Forty consecutive patients were included. Fifteen 
patients were treated with CE and 25 patients 
were treated with Y90. Median age was similar 
between both groups; 60 years (range: 38–89) 
for CE and 64 years (range: 29–87) for Y90 
(p = 0.798). Tumor extent (burden) was similar 
between the CE and 90Y groups (p > 0.9). The 
groups were also similar in the remaining char-
acteristics including gender, Eastern Cooperative 
Oncology Group (ECOG) score, extrahepatic 
disease, prior chemotherapy, concurrent chem-
otherapy and prior liver surgery or ablation. 
Baseline characteristics are s ummarized in table 1.
●● treatment factors & adverse events
Forty patients underwent 74 treatments (35 
treatments in the CE group and 39 in the Y90 
group). The majority of CE treatments were 
table 2. treatment factors.
Number of treatment courses ce Y90
  35  39
Type of treatment
Conventional TACE (n) 24 0
Drug-eluting beads (DEB-TACE) (n) 7 2†
– Y90 theraspheres 4† 26
– Y90 SIR-spheres 0 11
– Total 4 37





Level of branching (n)




Y90 activity delivered NA 1.56 GBq (0.41–5.31)
†Crossover treatment
Y90: Radioembolization; CE: Chemoembolization; DEB: Drug-eluting bead; TACE: Transarterial 
chemoembolization.
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performed in a conventional fashion (78%) with 
the remaining treatments using DEB loaded with 
doxorubicin (DEBDOX). Crossover treatments 
were performed in some patients if they did not 
respond to the initial treatment modality. In the 
CE group, there were four crossover treatments 
with Y90, while the Y90 group had two crosso-
ver treatments with DEBDOX. The majority of 
treatments in both groups were performed in a 
lobar fashion. The median Y90 activity delivered 
was 1.56 Gbq (0.41–5.31 Gbq). There were no 
reported cases of stasis with Y90 administration 
in the patient cohort.
Out of 33 treatments in the CE group, there 
were 7 (20%) treatment-related adverse events. 
Only three (9%) of those were high grade 
(≥grade 3). Out of 39 treatments in the Y90 
group, there were 10 (26%) treatment-related 
adverse events with 4 (10%) being high grade. 
Overall and high-grade adverse events were 
similar in both groups (p > 0.9999). The most 
common side effects were fever and abdominal 
pain in the CE group and abdominal pain in 
the Y90 group. High-grade adverse events in 
the CE group were represented by one patient 
with severe abdominal pain, one with refractory 
ascites and one with severe nausea and fatigue. In 
the Y90 group, two patients had severe abdomi-
nal pain with nausea and vomiting, one devel-
oped a gastric ulcer and one had liver failure with 
ascites and encephalopathy.
●● treatment efficacy
Treatment response is summarized in table 3. 
There was similar overall response rate for Y90 
and CE (Y90 4%; CE 7%; p > 0.999). DCR 
was also similar between both groups (Y90 47%; 
CE 48%; p > 0.999). Logistic regression did not 
reveal any background factor to independently 
associate with disease control (table 4). Only 
one patient in our study from the CE group was 
adequately downstaged for partial hepatectomy.
Discussion
ICC has demonstrated an increased incidence 
in the USA within recent years [21], with some 
authors citing a 128% increase in incidence 
from 1973–2012 [22]. This poses a challenging 
clinical problem. More than half of all patients 
present with unresectable disease [7] and have 
few effective options for management. For 
those patients who are suitable candidates, 
surgery is the standard of care and the only 
chance for a cure [23–25]. However, approxi-
mately 70% of patients who undergo curative-
intent surgical resection will experience disease 
recurrence in <20 months [26]. Traditionally, 
treatments including systemic therapy alone 
or in combination with radiation therapy have 
been employed in these patients [5,9,11]. These 
options are not curative while the associated 
toxicity and impact on quality of life is substan-
tial [27]. In response to this, locoregional IAT 
used for disease control or palliation is becom-
ing  increasingly common.
Two specific techniques, CE and Y90, have 
been increasingly used for treatment of unre-
sectable ICC. A fairly recent multi-institutional 
pooled cohort analysis that showed that IAT 
(Y90 and CE) for advanced ICC was safe and 
led to good disease control in the majority of 
patients (86%) [28]. However, despite the radi-
cally different cellular mechanisms of action, 
there has not been a clear establishment of the 
performance of one treatment over the other. 
The relatively low toxicity, potential to treat 
patients with significant tumor burden and fewer 
side effects are perceived advantages of using Y90 
embolization [29,30]. On the other hand, Y90 may 
provide less tumor necrosis than CE in patients 
with HCC [31], but this performance differ-
ence has not been shown in the ICC treatment 
population. Another disadvantage of Y90 is the 
singular available agent (Y90) for treatment. On 
the contrary, CE allows for a broader selection of 
table 3. image-based treatment response and progression.
  ce Y90 p-value
Response n = 15 n = 25  
Complete response 0 1 > 0.9999
Partial response 1 0 0.38
Stable disease 6 11 > 0.9999
Progression of disease 4 7 > 0.9999
Death from disease 1 0 0.38
Unknown status 3 5 > 0.9999
Y90: Radioembolization; CE: Chemoembolization.
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chemotherapeutic agents, which in turn enables 
tailored treatment for specific cancers, as is cur-
rently the trend in oncology [32–34]. Advocates 
for chemoembolization cite the above reasons 
as clear advantages favoring the use of CE for 
ICC; however, skeptics argue that ICC may not 
be vascular enough to enjoy the degree of effi-
cacy reported in the HCC literature. Y90, whose 
treatment efficacy is likely not solely depend-
ent on embolization, may be more ideal in the 
treatment of ICC and this reasoning drove our 
hypothesis. Given that chemoembolization and 
Y90 therapies are used interchangeably, there 
is a need to determine which therapy performs 
 better with less adverse effects.
Our study did not reveal a significant dif-
ference in all-grade and high-grade toxicity in 
patients treated with CE or Y90. In general, both 
therapies were well tolerated with a low rate of 
high-grade toxicity (9–10%). The most common 
adverse events in our study across both modali-
ties were abdominal pain, nausea, vomiting and 
fatigue, most of which were mild and resolved 
on their own with no delayed complications 
reported. This toxicity profile was in keeping 
with the rates reported in the literature [35]. The 
serious morbidities that we encountered, such as 
gastric ulcer (possibly from nontarget emboliza-
tion), ascites and severe abdominal pain, are rare 
and within reported rates in systematic reviews 
for both CE and Y90 [30,36–38].
Our study also found that CE and Y90 
achieved similar rates of tumor response and dis-
ease control in unresectable ICC. This finding 
may not be surprising to some, given that these 
treatments confer similar efficacy in other liver 
malignancies such as HCC [31]. We must indulge 
ourselves by saying that this observed parity in 
efficacy implies that the delivery of CE is not 
hindered by hypovascularity, which is a typical 
characteristic of ICC.
Both CE and Y90 have been evaluated on an 
individual basis for their efficacy in relation to 
many background variables. Good liver func-
tion, hypervascularity, solitary disease, tumor size 
(<8 cm) and previous systemic chemotherapy por-
tend a favorable prognosis for CE [32–34]. For Y90, 
reported significant prognostic variables associ-
ated with an improved survival include a good 
ECOG performance status (ECOG 0), peripheral 
tumor morphology, no portal vein thrombosis, 
solitary disease and tumor burden ≤25% [29,30,39]. 
Our study did not find any background variables 
associated with treatment response, despite the 
findings reported in other studies. This finding 
could conceivably be due to the small sample size 
and must be taken in context.
Other types of IAT that have been used for 
ICC include HAI and bland embolization. 
HAI chemotherapy represents a therapeutic 
approach that combines delivery of high doses 
of chemotherapy directly to the arterial circu-
lation where tumors derive most of their sup-
ply, minimizing the systemic toxicity of the 
chemotherapeutic agent [40]. Although this 
modality has offered good outcomes in terms 
of tumor response and survival [41], it is not as 
well tolerated as CE or Y90 [27]. Bland embo-
lization is used preferentially over CE in some 
centers [42]; however, no large studies have been 
reported. A small number of patients (n = 13) 
treated with bland embolization were included 
table 4. logistic regression for background variables affecting treatment outcomes.
Variable standard error  chi square p-value
Gender -64.281998 133503.79 0.9996
Extent (1,2,3,4)2–1  145.821079 398503.17 0.9997
Extent (1,2,3,4)3–2 -159.08415 384289.85 0.9997
Extrahepatic disease 48.1877063 182038.24 0.9998
ECOG0 108621.63 0.00 0.9999
ECOG1 45677.54 0.00 0.9997




Prior chemotherapy 245929.67 0.00 0.9996
Current chemotherapy -61.793528 106602.59 0.9995
Locoregional therapy -50.730397 88131.781 0.9995
Age 14936.628 0.00 0.9998
ECOG: Eastern Cooperative Oncology Group.
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in a multi-institutional analysis of patients with 
advanced ICC treated with IAT [28]. Median 
overall survival was 14 months, similar to 
that observed in the groups of patients treated 
with chemoembolization and Y90 (p = 0.46). 
Although HAI and bland embolization show 
promise, how these therapeutic options com-
pare to the more common modalities of CE and 
Y90 is still unknown.
There are several limitations to this study. First, 
this is a retrospective study and therefore suscep-
tible to bias including selection and population. 
Second, the patient population is very small, 
and therefore not powered for progression-free 
survival or overall survival. Moreover, survival 
was not assessed because many patients were lost 
to follow-up, and less than half of the subjects 
reached the end point (death,  progression-free 
survival).
conclusion
Chemoembolization and Y90 have a similar tox-
icity profile and comparable image-based disease 
control for the treatment of unresectable ICC. 
Robust prospective studies are needed to fur-
ther characterize the comparative performance 
of these intra-arterial therapies.
Future perspective
We believe that further discrimination between 
the role of Y90 and CE, and indeed other IAT 
will be determined by prospective, randomized 
controlled patient studies. In addition, current 
literature supports that continued development 
of these modalities will spark further investiga-
tion into the downstaging potential of Y90 and 
increased interest in the use of thermal ablation 
for the treatment of smaller lesions in cholan-
giocarcinoma. Use of imaging to explore micro-
vascular density and angiogenesis biomarkers 
may help tailor treatment to the vascularity of 
the tumor. This could include, for example, 
dedicated sequences defining vessel size, vessel 
density and blood volume on contrast-enhanced 
MRI. More efficient collaboration and develop-
ment of international registries will help spur 
even more research into this aggressive cancer.
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